8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $34M | -$46M | 0.0% | -152.2% | -$66M | — | $111M |
| 2024 | $69M | $7M | 0.0% | -38.1% | -$59M | — | $86M |
| 2023 | $49M | -$61M | 0.0% | -89.8% | -$86M | — | $117M |
| 2022 | $25M | -$112M | 0.0% | -248.3% | -$49M | $22M | $190M |
| 2021 | $116M | -$31M | 0.0% | -34.1% | -$16M | $2M | $144M |
| 2020 | $24M | -$109M | 0.0% | -452.2% | -$92M | — | $90M |
| 2019 | $22M | -$93M | 0.0% | -392.1% | -$96M | — | $181M |
| 2018 | $11M | -$46M | 0.0% | -440.2% | -$66M | — | $103M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $11M | -$18M | 0.0% | -83.7% | -$12M | — | $99M |
| Dec '25 | $34M | $20M | 0.0% | 36.6% | -$11M | — | $111M |
| Sep '25 | $13000 | -$22M | 0.0% | -158976.9% | -$15M | — | $45M |
| Jun '25 | $18000 | -$24M | 0.0% | -121538.9% | -$20M | — | $62M |
| Mar '25 | $29000 | -$21M | 0.0% | -76248.3% | -$19M | — | $77M |
| Dec '24 | $638000 | -$18M | 0.0% | -3894.4% | -$19M | — | $86M |
| Sep '24 | $576000 | -$16M | 0.0% | -3693.6% | -$6M | — | $99M |
| Jun '24 | $50M | $33M | 0.0% | 48.4% | -$15M | — | $124M |
| Mar '24 | $18M | $9M | 0.0% | -23.8% | -$19M | — | $138M |
| Dec '23 | $7M | -$16M | 0.0% | -211.6% | -$8M | — | $117M |
| Sep '23 | $13M | -$8M | 0.0% | -94.2% | -$23M | — | $122M |
| Jun '23 | $20M | -$12M | 0.0% | -15.8% | -$22M | — | $138M |
| Mar '23 | $9M | -$25M | 0.0% | -152.1% | -$32M | $22M | $158M |
| Dec '22 | $11M | -$28M | 0.0% | -114.3% | -$22M | $22M | $190M |
| Sep '22 | $7M | -$24M | 0.0% | -199.3% | $28M | $22M | $212M |
| Jun '22 | $4M | -$31M | 0.0% | -773.7% | -$25M | $22M | $184M |
| Mar '22 | $3M | -$28M | 0.0% | -824.1% | -$30M | $2M | $116M |
| Dec '21 | $6M | -$22M | 0.0% | -484.7% | -$25M | $2M | $144M |
| Sep '21 | $24M | -$11M | 0.0% | -48.0% | -$25M | — | $160M |
| Jun '21 | $69M | $22M | 0.0% | 31.4% | -$33M | — | $174M |
How the market has priced DTIL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, PRECISION BIOSCIENCES INC's revenue has grown 7.1% per year. These are computed facts, not advice.
As of FY2025, PRECISION BIOSCIENCES INC reported — of total debt against $111M of cash; operating income covered interest expense -36.7×.
In FY2025, gross margin was —, operating margin -152.2%, and net margin -133.4%.
As of Jun '26, PRECISION BIOSCIENCES INC traded at a price-to-earnings ratio of about 19.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.